Primary Axillary Hyperhidrosis Clinical Trial
Official title:
A Comparative Study for Efficacy and Safety Between Fractional Micro-Needle Radiofrequency (FRM) and Intradermal Botulinum Toxin A for the Treatment of Primary Axillary Hyperhidrosis
Verified date | February 2017 |
Source | Mae Fah Luang University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Because of the limiting data about an efficacy and safety of fractional radiofrequency for the treatment of hyperhidrosis, this study aim to compare clinical efficacy by Hyperhidrosis Disease Severity Score (HDSS) between Fractional Microneedle Radiofrequency device and intradermal Botulinum toxin type A injection for the treatment of primary axillary hyperhidrosis. The secondary objectives to determine the improvement change of iodine starch test, total amount of sweat production by trans-epidermal water loss (TEWL), patient's satisfaction and their quality of life by Dermatology Life Quality Index and side effect between the groups.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 31, 2017 |
Est. primary completion date | December 31, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: Male or female subjects, age between 18-60 years - Healthy volunteers - Subjects who have experienced with excessive sweating on both sides of axillary areas and have a positive result for iodine starch test on the screening day - Willing to participant into the study and voluntary to sign in the informed consent form Exclusion Criteria: Active bacterial or fungal infection over tested area / axillae - Pregnancy and breast feeding - Previously underwent the surgical treatment such as radical resection of sweat glands for primary axillary hyperhidrosis - Currently being treated with intradermal botulinum toxin type A injection at axillary area for less than 12 months - Currently being inserted the cardiac pace maker or any other internal electronic devices - Secondary hyperhidrosis caused by hyperthyroidism, drug induced, abnormal autonomic or neurological disorder that affect sweat gland - Allergy to botulinum toxin type A - Known contact allergy to iodine - Unable to follow and comply to the study protocol |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Mae Fah Luang University Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change of Hyperhidrosis disease severity score (HDSS) at week-12 with the baseline | Hyperhidrosis disease severity score will be assessed by study subjects that is categorized to 4 levels; (1) my axillary sweating is never noticeable and never interferes with my daily activities (2) my axillary sweating is tolerable but sometimes interferes with my daily activities (3) my axillary sweating is barely tolerable and frequently interferes with my daily activities (4) my axillary sweating is intolerable and always interferes with my daily activities | 12 weeks | |
Secondary | Iodine starch test | Qualitative test used to evaluate sudo-motor function (sweating) which method is to apply iodine solution to the skin. Once dry, the area is dusted with cornstarch or potato flour then sweating is encouraged. When sweat reaches the surface of the skin the starch and iodine combine causing a dramatic color change from yellow to dark blue allowing sweat production to be actively visualized. Photograph from iodine starch test will be assessed by two independent clinical assessors who are blinded to study protocol and grading with score. The investigators will prepare the photo with pre- and post-treatment set. Each set will contain 6 photos, 3 photos from the left and 3 photos from the right. Prepare by using Microsoft PowerPoint program, on each slide will contain 2 photos, pre-treatment photos on the left and post treatment photos on the right. The paired photos will be assessed and graded the score at different time points (4 and 12 weeks) on each side of axilla |
baseline, week 4 and week 12 | |
Secondary | Participants' satisfaction assessment | An assessment will be determined at the endpoint visit (4th-12thweek) after the treatment by study subjects by Quartile rating scale on each side of axilla. Quartile rating scale by comparing with the baseline that is categorized to 4 levels; (3) greatly satisfy with treatment result (2) moderately satisfy with treatment result (1) slightly satisfy with treatment result (0) No different with treatment result. | week 4 and week 12 | |
Secondary | Adverse effect | Side effect | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03627468 -
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
|
Phase 3 | |
Completed |
NCT03658616 -
Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.
|
Phase 3 | |
Completed |
NCT02286765 -
Ulthera® System for Treating Axillary Hyperhidrosis
|
N/A | |
Completed |
NCT04599907 -
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
|
N/A | |
Completed |
NCT03037788 -
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
|
Phase 1 | |
Terminated |
NCT01722461 -
A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis
|
N/A | |
Completed |
NCT05863104 -
Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis
|
Phase 2 | |
Completed |
NCT02823340 -
Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis
|
N/A | |
Not yet recruiting |
NCT04159610 -
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis
|
Phase 2 | |
Completed |
NCT01799824 -
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
|
Phase 2 | |
Completed |
NCT03785587 -
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
|
Phase 2 |